BioStock: Lipum to carry out an IPO during 2021

Report this content

During 2020, Covid-19 caused significant difficulties for many life science companies. However, Umeå-based Lipum was quick to change their plans and adapt to the prevailing circumstances early on in the pandemic. This proved to be a clever move and during 2020, important steps were taken towards the first clinical study with the drug candidate SOL-116. BioStock contacted Lipum’s CEO Einar Pontén to find out more about the past year and the plans for 2021. 

Read the full article at

This is a press release from BioStock - Connecting Innovation & Capital.


Documents & Links

Quick facts

BioStock: Lipum to carry out an IPO during 2020
Tweet this